3.4. ctDNA hVAF as a Biomarker for Atezolizumab Response
The ctDNA hVAF of 64 ctDNA samples at C0 and 48 paired samples at C4/EOT was measured (At the cut-off value at C0 (3.9%), there was no difference in the DCB rate (high 13.8% vs. low 22.9%; There was no difference in the PFS according to the hVAF level at C0; however, the subgroup with no change or a decreased hVAF level from C0 to C4/EOT had a longer PFS compared with the subgroup with an increased hVAF level (